BRIEF-Erasca Announces Updated Preliminary Phase 1 Data, Registration-Enabling Plans For Potentially Best-In-Class Pan-Ras Molecular Glue Eras-0015 In Kras-Mutant Solid Tumors

Erasca, Inc.

Erasca, Inc.

ERAS

0.00

July 13 (Reuters) - Erasca Inc ERAS.O:

  • ERASCA ANNOUNCES UPDATED PRELIMINARY PHASE 1 DATA AND REGISTRATION-ENABLING PLANS FOR POTENTIALLY BEST-IN-CLASS PAN-RAS MOLECULAR GLUE ERAS-0015 IN KRAS-MUTANT SOLID TUMORS

  • ERASCA INC: ADDITIONAL ERAS-0015 MONOTHERAPY AND COMBINATION DATA EXPECTED H1 2027

  • ERASCA - PLANS REGISTRATION-ENABLING LUNG CANCER TRIAL IN H1 2027; PHASE 3 PANCREATIC CANCER TRIAL IN 2027

Source text: ID:nGNXrdGNh

Further company coverage: ERAS.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.